Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Assets (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Assets for 3 consecutive years, with $16.1 million as the latest value for Q4 2025.

  • Quarterly Assets rose 4.68% to $16.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Dec 2025, up 4.68% year-over-year, with the annual reading at $16.1 million for FY2025, 4.68% up from the prior year.
  • Assets hit $16.1 million in Q4 2025 for Mangoceuticals, down from $16.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $21.8 million in Q1 2025 to a low of $301447.0 in Q1 2024.
  • Historically, Assets has averaged $10.9 million across 3 years, with a median of $15.0 million in 2024.
  • Biggest five-year swings in Assets: plummeted 92.67% in 2024 and later soared 7116.48% in 2025.
  • Year by year, Assets stood at $1.1 million in 2023, then surged by 1362.75% to $15.4 million in 2024, then grew by 4.68% to $16.1 million in 2025.
  • Business Quant data shows Assets for MGRX at $16.1 million in Q4 2025, $16.5 million in Q3 2025, and $20.8 million in Q2 2025.